Zimmer Holdings Inc

Most Recent

  • uploads///recommendations
    Company & Industry Overviews

    What Wall Street Analysts Recommend for Dentsply Sirona

    Dentsply Sirona (XRAY), one of the leading dental technology providers in the United States, recently outlined a turnaround plan to recover from the company’s disappointing performance in recent years.

    By Sarah Collins
  • uploads///kyle sterk  unsplash
    Company & Industry Overviews

    ALGN Stock Surpasses the S&P 500 Index’s Year-to-Date Gain

    On September 28, Align Technology (ALGN) posted an ~74% increase year-to-date. In the same period, the S&P 500 Index has returned ~9%.

    By Sarah Collins
  • uploads///types of moats
    Macroeconomic Analysis

    The Ins and Outs of Moat Investing

    Stock selection, a cornerstone of the moat investment philosophy, has driven much of the recent success of the Morningstar® Wide Moat Focus Index.

    By VanEck
  • uploads///STOCK PRICE
    Company & Industry Overviews

    BD’s Stock Price Performance after Recent 52-Week High

    On December 28, Becton, Dickinson and Company (BDX), or BD, closed trading on the day at $214.32 per share. Currently, BD stock’s 50-day moving average stands at $221.22.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Align Technology Traded at Its 52-Week High in September

    Align Technology was trading at its 52-week high of $398.88 on September 25. The stock reported its 52-week low of $180.31 on September 28, 2017.

    By Sarah Collins
  • uploads///recommendation
    Company & Industry Overviews

    Wall Street Analysts Are Still Bullish on ALGN Stock

    Align Technology (ALGN) stock hasn’t received any recommendation updates since the stock was upgraded by several analysts in July.

    By Sarah Collins
  • uploads///hush naidoo  unsplash
    Company & Industry Overviews

    Trade War Fears Triggered Medtronic’s Stock Decline on March 23

    Following heightened concerns of a US–China trade war, Medtronic (MDT) stock hit its 52-week low of $76.41 on March 23, 2018.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Will Dentsply Sirona Stock Recover from Recent Declines?

    On April 6, 2018, Dentsply Sirona (XRAY) ended at a closing price of $49.02 per share.

    By Sarah Collins
  • uploads///innovation strategies
    Company & Industry Overviews

    How Johnson & Johnson’s Partnerships Enhance Customer Value

    Johnson & Johnson’s key innovation strategies include creating value through strategic customer partnerships and solutions.

    By Sarah Collins
  • uploads///revenue estimates
    Company & Industry Overviews

    Stryker’s Recent Stock Price Movement: Upside Potential?

    Stryker stock has registered slightly volatile activity in the past few months. However, the stock largely remains on a bullish trajectory.

    By Sarah Collins
  • uploads///COMPLEMENTARY PORTFOLIO
    Company & Industry Overviews

    Effect of Claris Injectables Acquisition on Baxter’s 2017 Growth

    On July 27, 2017, Baxter International (BAX) completed the acquisition of Claris Injectables, which is expected to help expand and strengthen Baxter’s core capabilities.

    By Sarah Collins
  • uploads///analyst recommendations
    Company & Industry Overviews

    Wall Street Maintains ‘Strong Buy’ Recommendation for Stryker

    Analysts’ recommendations Stryker (SYK) has registered strong results over the last few quarters and has been expanding at a fast pace through organic and inorganic growth. The company has made a number of acquisitions and expanded its market presence across product lines and regions. Its most recent earnings results were reported on October 26, 2017. For details, read […]

    By Sarah Collins
  • uploads///tooth _
    Earnings Report

    Analysts Cut Their Targets for XRAY ahead of Its 1Q18 Results

    Dentsply Sirona, one of the leading dental technology providers in the United States, will announce its 1Q18 earnings results on May 7.

    By Sarah Collins
  • uploads///key strategies
    Company & Industry Overviews

    Understanding Zimmer Biomet’s Latest Dividend Announcement

    On December 18, 2017, Zimmer Biomet Holdings (ZBH) announced a quarterly cash dividend of $0.24 per share for fiscal 4Q17.

    By Sarah Collins
  • uploads///US Investment Grade Bond Market Issuance
    Company & Industry Overviews

    High-grade corporate bonds hit second-highest issuance of 2015

    Corporate investment-grade borrowing marginally declined to $62.34 billion in the week to March 13, 2015, the second-highest issuance in 2015.

    By David Ashworth
  • uploads///STOCK PRICE
    Earnings Report

    Understanding JNJ’s Latest Stock Price Rise

    On July 20, 2017, JNJ stock was trading at its 52-week high of $137.1, which was ~25.4% above its 52-week low of $109.3 on December 7, 2016.

    By Sarah Collins
  • uploads///highlights
    Company & Industry Overviews

    Behind JNJ’s Recent Stock Price Performance: Is More Growth Coming?

    Johnson & Johnson (JNJ) has seen a few disappointing quarterly performances, but on October 17, when JNJ announced its 3Q17 results, the stock gained 3.4%.

    By Sarah Collins
  • uploads///Align technolgies
    Company & Industry Overviews

    Align Technology Stock Recovers after Tanking Last Week

    Align Technology stock (ALGN) took a massive hit after Q2 earnings. So what was behind the massive decline, and what’s helping the stock recover?

    By Sushree Mohanty
  • uploads///core strategies
    Company & Industry Overviews

    How Stryker’s Margins Are Driven by Its CTG Program

    Cost transformation for growth (or CTG) is Stryker’s program that focuses on driving leveraged growth by structural cost optimization.

    By Sarah Collins
  • uploads///equipment _
    Company & Industry Overviews

    FDA Approves Zimmer Biomet’s ROSA, Stock Up 2.6%

    Today, Zimmer Biomet Holdings’ (ZBH) ROSA Knee System received FDA 510(k) clearance for robotically assisted total knee replacement surgeries.

    By Daniel Collins
  • uploads///BSX
    Company & Industry Overviews

    Why Analysts Are Mostly Positive on Boston Scientific Stock

    Boston Scientific stock rose from $24.79 at the close of market on December 29, 2017, to $34.80 at the close of market on November 23.

    By Daniel Collins
  • uploads///SYK
    Company & Industry Overviews

    Analysts Remain Bullish on Stryker Stock

    In November 2018, of the total 29 analysts covering Stryker (SYK), 19 analysts gave Stryker stock a “buy” or higher rating, and ten analysts have given it a “hold” rating.

    By Kenneth Smith
  • uploads///doctors office _
    Company & Industry Overviews

    How Stryker Is Positioned in November

    Stryker generated total revenues of $3.24 billion in the third quarter of 2018 as compared to $3.01 billion in the comparable period of 2017.

    By Kenneth Smith
  • uploads///SYk ana reco
    Earnings Report

    What Analysts Recommend for Stryker Stock

    Of the total 28 analysts covering Stryker (SYK) in October 2018, 19 analysts have given the stock a “buy” or higher rating, and nine analysts have given Stryker a “hold” rating.

    By Kenneth Smith
  • uploads///hospital _
    Earnings Report

    Zimmer Biomet Holdings: Revenue Trends ahead of Its Q3 Earnings

    Zimmer Biomet (ZBH) plans to release its Q3 earnings on October 26. Analysts expect ZBH to generate third-quarter revenues of $1.8 billion.

    By Daniel Collins
  • uploads///VAR FCF
    Earnings Report

    What to Expect from Varian’s Bottom Line in Q4 2018

    Varian Medical Systems (VAR) is expected to report net income of $105.05 million in the fourth quarter of fiscal 2018.

    By Kenneth Smith
  • uploads///ISRG RD
    Earnings Report

    How Intuitive’s Bottom Line Is Expected to Look in Q3 2018

    Intuitive Surgical’s (ISRG) cost of goods sold is expected to rise 16.82% to $265.76 million in the third quarter of 2018.

    By Kenneth Smith
  • uploads///VRAY ana reco
    Company & Industry Overviews

    What ViewRay’s Valuation Trend Indicates

    In September, of the seven analysts covering ViewRay (VRAY), six have given its stock “buy” or higher ratings, and one analyst has given it a “sell” rating.

    By Kenneth Smith
  • uploads///TFX
    Company & Industry Overviews

    Analysts Still Bullish on Teleflex Stock

    Teleflex’s (TFX) interest expenses increased from $19.89 million in the second quarter of 2017 to $26.65 million in the second quarter of 2018.

    By Kenneth Smith
  • uploads///medic _
    Earnings Report

    Haemonetics’s Fiscal Q1 Earnings Surpass Analyst Estimates

    Haemonetics reported an 8.7% YoY increase in revenues to $229.3 million during Q1 2019 as compared to revenues of $210.9 million during Q1 2018.

    By Mike Benson
  • uploads///blood _
    Earnings Report

    What Analysts Expect from Haemonetics in Q1 2019

    Haemonetics is expected to report 4.3% growth in revenues to $219.9 million during Q1 2019 as compared to $210.9 million during Q1 2018.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Commercial Launch of NexSys PCS May Boost Haemonetics’s Revenues

    Haemonetics is also involved in plasma donor center experience programs that involve the use of NexSys PCS device and YES technology.

    By Margaret Patrick
  • uploads///OPERATIONAL EXCELLENCE
    Company & Industry Overviews

    Here’s What Dentsply Sirona Has Planned for Its Margins

    Dentsply Sirona has a new management team that is working toward a more successful integration because it delivered lower-than-expected synergies in 2017.

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Reading Dentsply Sirona’s Recent Stock Performance

    On March 13, 2018, Dentsply Sirona closed trading at a price of $57.80 per share. The stock registered its 52-week high of $68.98 on November 28, 2017.

    By Sarah Collins
  • uploads///peter kasprzyk  unsplash
    Company & Industry Overviews

    Why Is Wall Street Still Upbeat on Dentsply Sirona’s Growth Potential in 2018?

    Dentsply Sirona is a leading dental technology, equipment, and consumables provider in the US. But it has been going through some tough times.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    What’s Abbott Laboratories’ Current Valuation?

    As of March 7, 2018, Abbott Laboratories (ABT) was trading at a forward PE (price-to-earnings) ratio of 20.8x, while the stock has a PE ratio of 59x.

    By Sarah Collins
  • uploads///medtech growth comparison
    Company & Industry Overviews

    Where Is SYK Stock Headed after Its Recent All-Time Highs?

    On February 26, 2018, Stryker (SYK) closed trading at $165.77. The stock was trading at its all-time high of $170 on January 29, 2018.

    By Sarah Collins
  • uploads///SDC
    Company & Industry Overviews

    Align Technology and Its SmileDirectClub Partnership

    In 4Q17, Align Technology reported a sequential decline in its shipments of non-Invisalign SDC aligners to SDC.

    By Sarah Collins
  • uploads///strategic priorities
    Company & Industry Overviews

    Align Technology to Execute on Key Strategic Priorities in 2018

    Align Technology (ALGN) has been growing at a fast pace while it executes its strategic priorities around the world.

    By Sarah Collins
  • uploads///Invisalign shipment trend
    Company & Industry Overviews

    Align Technology’s Invisalign: Average Selling Price and Volumes

    Increases in Align Technology’s (ALGN) Invisalign volumes and ASP were the major factors driving the company’s sales growth.

    By Sarah Collins
  • uploads///ITGR geographic segments
    Company & Industry Overviews

    The Geographic Segments of Integer Holdings Corporation

    Integer Holdings Corporation provides custom battery packs to energy, military, and environmental markets for use in extreme environments.

    By Kenneth Smith
  • uploads///analyst recommendations
    Company & Industry Overviews

    Align Technology: Analyst Ratings and Recommendations

    Of the 12 investment research firms following ALGN stock, ten of them have given the stock “buy” or “strong buy” recommendations.

    By Sarah Collins
  • uploads///Q_highlights
    Company & Industry Overviews

    Inside Abbott Laboratories’ 4Q17 Earnings Results: Key Highlights

    Abbott Laboratories (ABT) reported sales of $7.6 billion and adjusted diluted EPS (earnings per share) of $0.74 for fiscal 4Q17.

    By Sarah Collins
  • uploads///EPS ESTIMATES
    Earnings Report

    ZBH’s 4Q17 Earnings Results Meet Analysts’ Estimates

    Zimmer Biomet Holdings announced its 4Q17 and 2017 results on January 30. The company’s sales exceeded analysts’ estimates, while its adjusted earnings per share managed to meet estimates.

    By Sarah Collins
  • uploads///guidance
    Company & Industry Overviews

    A Look at Johnson & Johnson’s 2018 Guidance

    Johnson & Johnson (JNJ) provided 2018 guidance during the company’s earnings results release on January 23, 2018.

    By Sarah Collins
  • uploads///EARNINGS ESTIMATES
    Earnings Report

    Will ZBH Beat Wall Street Earnings Estimates in 4Q17?

    Zimmer Biomet Holdings (ZBH) accounts for ~0.17% of the total holdings of the Vanguard International High Dividend Yield ETF (VYMI). Zimmer Biomet Holdings plans to announce its 4Q17 and fiscal 2017 earnings results on January 30.

    By Sarah Collins
  • uploads///STOCK PRICE
    Earnings Report

    ABT Stock Trading Near Its All-Time High: What’s Driving Growth?

    Abbott Laboratories (ABT) is currently trading near its all-time high of $59.60 per share, which was reported on January 4, 2018.

    By Sarah Collins
  • uploads///RECMMENDATIONS
    Company & Industry Overviews

    Wall Street Issues Majority ‘Buy’ Ratings on Align Technology

    On December 29, 2017, according to 12 investment brokerage firms which were part of a Reuters survey, Align Technology stock has received a “buy” rating from 11 analysts.

    By Sarah Collins
  • uploads///value chain
    Company & Industry Overviews

    Align Technology’s Customer Acquisition Strategy Driving Market Growth

    In 3Q17, Align Technology trained nearly 1,000 doctors in China.

    By Sarah Collins
  • uploads///MARKET OPPORTNITY
    Company & Industry Overviews

    Align Technology’s Growth Prospects amid Increasing Competition

    The Chinese market is Align Technology’s major growth driver. However, the company is starting to witness strong competition from startups focused on the clear aligners market.

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Stryker’s Stock Rally Continues with 52-Week High Yesterday

    On January 9, Stryker (SYK) traded at a 52-week high of $164.2 per share. The stock ended trading with a closing price of $160.4.

    By Sarah Collins
  • uploads///mcms
    Company & Industry Overviews

    Medtronic’s New Telehealth Solution for Veterans

    On November 27, 2017, Medtronic (MDT) announced the launch of its new telehealth solutions as part of its contract with the United States Department of Veterans Affairs (or VA).

    By Sarah Collins
  • uploads///business profile
    Company & Industry Overviews

    Discussing the Recent Management Changes at Medtronic

    On December 20, 12 of 24 analysts surveyed by Reuters rated Medtronic (MDT) stock as a “buy,” and the remaining 12 analysts recommended a “hold.” There were no “sell” ratings given to MDT stock.

    By Sarah Collins
  • uploads///GOP TAX BILL
    Healthcare

    How the Corporate Tax Rate Cut Could Affect R&D in the Medtech Industry

    The repeal of the tax deduction for high medical expenses may reduce the number of taxpayers opting for costly medical technologies and services.

    By Sarah Collins
  • uploads///FREE CASH FLOWS
    Company & Industry Overviews

    The Free Cash Flow Estimates of Medtronic in 2018 and Beyond

    In fiscal 2Q18, Medtronic used a portion of its divestiture proceeds toward stock buybacks. The total share repurchases in the quarter came in at ~$568.0 million.

    By Sarah Collins
  • uploads///EMERGING MARKET OPORTUNITY
    Company & Industry Overviews

    Emerging Markets Growth Is Driving Medtronic’s Geographic Strategy

    In fiscal 2Q18, Medtronic registered sales of ~$1.1 billion from emerging markets.

    By Sarah Collins
  • uploads///operatingmargin
    Company & Industry Overviews

    What’s Driving BD’s Operating Margin Expansion

    Overview BD (BDX) has registered strong operating margin expansion in recent years. Its margin improved by 100 basis points in fiscal 2015 and 200 basis points in fiscal 2016. In fiscal 2017, BD’s margin expanded by ~180 basis points. In 4Q17, BD’s operating margin grew ~14.6% YoY (year-over-year), limited by 700 basis points due to the divestiture of BD’s […]

    By Sarah Collins
  • uploads///OPERATIONAL PLANS
    Company & Industry Overviews

    Zimmer Biomet’s Plan to Revive Growth amid Supply Disruptions

    Zimmer Biomet Holdings has laid down a dual sourcing strategy to resolve production issues at its Warsaw facility.

    By Sarah Collins
  • uploads///GLOBAL FOOTPRINTS
    Company & Industry Overviews

    Asia-Pacific Still Zimmer Biomet’s Strongest Geography

    Zimmer Biomet Holdings witnessed a strong performance in its Asia-Pacific region. It contributed 16% to the company’s total sales.

    By Sarah Collins
  • uploads///mako
    Earnings Report

    How Mako Robots Are Driving Stryker’s Sales in 2017

    Mako sales in 3Q17 In 3Q17, Stryker sold 33 Mako robots, compared with 30 robots in 3Q16. In 2Q17, Stryker installed 26 Mako robots. Of these 33 robots, 23 were installed in the United States. Around 40% of US sales are expected to be in competitive accounts. Stryker is training surgeons on its total knee application […]

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Understanding BD’s Recent Stock Performance

    BD has a 50-day moving average of $197.25, while its 200-day moving average is $192.35.

    By Sarah Collins
  • uploads///leading portfolio
    Company & Industry Overviews

    Developments in Dentsply Sirona’s Digital Dentistry Portfolio

    On September 20, 2017, Dentsply Sirona (XRAY) announced an enhancement to its Galileos Implant software.

    By Sarah Collins
  • uploads///leading portfolio
    Company & Industry Overviews

    Dentsply Sirona’s Newly Launched Cerec Zirconia Meso Block

    In August 2017, Dentsply Sirona (XRAY) launched its Cerec Zirconia Meso Block for creating customized screw-retained crowns.

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    What Analysts Are Recommending for Dentsply Sirona

    According to the recommendations of 15 brokerage firms, 60.0% (or nine) of them have rated Dentsply Sirona (XRAY) a “buy,” and 33.0% (or five) have rated it a “hold.”

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    Why Most Analysts Recommend a ‘Buy’ on ZBH Stock

    ZBH stock’s consensus 12-month target price is $135.6, which amounts to about a 17.5% return potential over its price of $115.5 on September 19, 2017.

    By Sarah Collins
  • uploads///knee market share
    Company & Industry Overviews

    ZBH’s Persona Partial Knee Launch Expands Knee Implant Portfolio

    On September 11, 2017, Zimmer Biomet Holdings (ZBH) announced the launch of its Persona Partial Knee System.

    By Sarah Collins
  • uploads///investments
    Company & Industry Overviews

    Strategic Investments Drive Intuitive Surgical’s Future Growth

    Intuitive Surgical focused on accelerating its strategic investments in recent years. It wants to expand across low-cost and untapped markets.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    What’s Behind the Recent Slump in ZBH Stock Price?

    Zimmer Biomet closed trading at price of $113.1 on August 30. The stock has a 50-day moving average of $119.95 and a 200-day moving average of $120.95.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Taking a Look at Stryker’s Recent Stock Price Performance

    On August 31, Stryker (SYK) closed trading at a closing price of $139.3. It has a 50-day moving average of $144.7 and a 200-day moving average of $137.5.

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    Which Way Are Zimmer Biomet’s Analysts Leaning after 2Q17?

    Of the 29 brokerage firms tracking Zimmer Biomet, 18 (62%) analysts gave ZBH stock a “buy” rating, while nine (~31%) provided a “hold” rating.

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    Wall Street’s Upbeat on Boston Scientific: Most Recommend a ‘Buy’

    Wall Street analysts’ lowest one-year target price for Boston Scientific (BSX) stock is $24, representing a -11.4% maximum downside risk potential for the next year.

    By Sarah Collins
  • uploads///sage
    Company & Industry Overviews

    Stryker Stock Falls Due to the Impact of the Sage Products Recall

    On August 23, Stryker (SYK) announced a voluntary product recall of specific lots of oral care products that form part of the company’s Sage business unit.

    By Sarah Collins
  • uploads///ma
    Company & Industry Overviews

    What Zimmer Biomet’s Leadership Transition Could Mean for Its Core Growth Strategy

    In July 2017, David Dvorak stepped down as chief executive officer and president of Zimmer Biomet (ZBH) and resigned from its board of directors.

    By Sarah Collins
  • uploads///STOCK PRICE
    Earnings Report

    Medtronic’s Stock Price Falls in Response to 1Q18 Revenue Miss

    Stock movement On August 22, 2017, Medtronic (MDT) announced its 1Q18 earnings results. Medtronic exceeded analysts’ EPS (earnings per share) estimate but missed the revenue estimate. Medtronic’s stock price fell ~0.6% in the pre-market trading session following the announcement. Since its fiscal 4Q17 results announcement on May 25, 2017, Medtronic’s stock has fallen ~6.5%. In […]

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    What Do Analysts Recommend for Dentsply Sirona?

    Based on the recommendations of 16 brokerage companies, around 63% (or ten) of the analysts provided a “buy” recommendation for Dentsply Sirona.

    By Sarah Collins
  • uploads///PROJECTIONS
    Company & Industry Overviews

    Discussing Dentsply Sirona’s Updated 2017 Guidance

    Dentsply Sirona made a downward revision to its fiscal 2017 guidance during the company’s 2Q17 earnings results announcement on August 9, 2017.

    By Sarah Collins
  • uploads///REVENUES BY SEGMENT
    Company & Industry Overviews

    Dentsply Sirona’s Technologies Segment Sales Declined in 2Q17

    In 2Q17, Dentsply Sirona’s (XRAY) Technologies business contributed ~44% to the company’s total revenues and registered sales of ~$439 million.

    By Sarah Collins
  • uploads///REVENUES BY SEGMENT
    Company & Industry Overviews

    Dental and Healthcare Consumables Grew but Missed Expectations in 2Q17

    In 2Q17, Dentsply Sirona’s (XRAY) Dental and Healthcare Consumables business contributed ~56% to the company’s total revenues and registered sales of ~$554 million.

    By Sarah Collins
  • uploads///revenue estimates
    Earnings Report

    Stryker Exceeded Analysts’ Sales Estimates in 2Q17

    On July 27, 2017, Stryker (SYK) released its 2Q17 earnings. The company reported strong earnings and exceeded analysts’ expectations.

    By Sarah Collins
  • uploads///GE Additive Manufacturing
    Company & Industry Overviews

    Stryker’s Partnership with GE: Growth in Additive Manufacturing

    In June 2017, Stryker (SYK) entered into a partnership with General Electric (GE) to expand its additive manufacturing business.

    By Sarah Collins
  • uploads///Chart  ABT
    Miscellaneous

    A Look at Abbott Laboratories Stock for 2Q17

    Wall Street analysts estimate that Abbott Laboratories (ABT) stock has the potential to return ~6.1% over the next 12 months.

    By Mike Benson
  • uploads///growth drivers
    Company & Industry Overviews

    FDA Warning Letter to Zimmer Biomet Resolved, Boosts Confidence

    On June 13, 2017, Zimmer Biomet (ZBH) announced that the FDA warning letter issued in June 2015 relating to its Zhejiang manufacturing facility in China has been closed.

    By Sarah Collins
  • uploads///knee market share
    Company & Industry Overviews

    Zimmer Biomet Expands Portfolio with X-Ray–Based Knee System

    On June 28, 2017, Zimmer Biomet announced the launch of its X-PSI Knee System, an X-ray–based surgical system that allows patient-specific implant positioning.

    By Sarah Collins
  • uploads///geographic segmentationn
    Company & Industry Overviews

    How Stryker Plans to Capture the International Markets

    Most of Stryker’s emerging market sales are from China. However, Europe and emerging markets sales have witnessed high growth in recent quarters.

    By Sarah Collins
  • uploads///mako sales
    Company & Industry Overviews

    Stryker’s Plan to Strengthen Position in Robotics Market Space

    At the end of 1Q17, Stryker had placed 350 robots in the United States and completed about 1,400 MAKO total knee replacements.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    How Zimmer Biomet Stock Has Performed Recently

    Zimmer Biomet Holdings (ZBH) was trading at $118.40 on May 30, 2017. It has a 50-day moving average of $119.70 and a 200-day moving average of $114.20.

    By Sarah Collins
  • uploads///CAPITAL ALLOCATION
    Company & Industry Overviews

    Zimmer Biomet’s Capital Allocation Strategy to Create Value

    In February 2016, Zimmer Biomet authorized up to $1.0 billion of the company’s common stock for share repurchases, all of which remains authorized to date.

    By Sarah Collins
  • uploads///ma
    Company & Industry Overviews

    Zimmer Biomet’s Inorganic Growth Strategy Is Helping Performance

    In October 2016, Zimmer Biomet Holdings announced the acquisition of the RespondWell telerehabilitation platform.

    By Sarah Collins
  • uploads///profitability
    Earnings Report

    How Dentsply Sirona’s Profitability Metrics Looked in 1Q17

    Dentsply Sirona’s (XRAY) 1Q17 earnings and revenue failed to meet analysts’ estimates. The company reported a fall in its organic revenue.

    By Sarah Collins
  • uploads///revenues by segment
    Earnings Report

    Dentsply Sirona’s New Growth Strategy to Accelerate Digital Dentistry Penetration

    Dentsply Sirona is the largest dental equipment and solutions manufacturer in the United States. Digital dentistry is a megatrend in the market.

    By Sarah Collins
  • uploads///product segments
    Earnings Report

    What Dragged Down Technology Business Sales in 1Q17?

    Dentsply Sirona’s Technology segment sales Dentsply Sirona (XRAY) reported ~$900 million of revenues worldwide in 1Q17. Of that, ~$389 million was generated through Dentsply Sirona’s Technology segment, which contributed ~43.2% to Dentsply Sirona’s total revenues. On a constant currency basis, the Technology segment’s sales declined by approximately 8.1%. The segment’s sales were flat in Europe. The […]

    By Sarah Collins
  • uploads///recommendations
    Earnings Report

    What Analysts Recommend for Stryker after 1Q17 Results

    The consensus 12-month target price for Stryker is $141, a ~3.5% return potential.

    By Sarah Collins
  • uploads///core strategies
    Earnings Report

    What Are Stryker’s Key Growth Drivers for 2Q17?

    Stryker has registered strong revenues and earnings in the last few quarters.

    By Sarah Collins
  • uploads///DEAL RATIONALE
    Company & Industry Overviews

    A Look at BD’s Deal Rationale in Its C.R. Bard Acquisition

    BD’s acquisition of C.R. Bard is aimed at providing a comprehensive product portfolio to customers at more reasonable costs and enhanced efficiency.

    By Sarah Collins
  • uploads///STOCK PRICE
    Earnings Report

    How ZBH Stock Has Performed Recently

    Zimmer Biomet Holdings (ZBH) was trading at $123.3 as of April 24, 2017.

    By Sarah Collins
  • uploads///REVENUE ESTIMATES
    Earnings Report

    Why Zimmer Biomet Could See Revenue Growth in 1Q17

    Wall Street analysts expect Zimmer Biomet’s 1Q17 revenue to be about $1.96 billion, a ~3% increase on a YoY (year-over-year) basis.

    By Sarah Collins
  • uploads///medical device segment
    Company & Industry Overviews

    Johnson & Johnson’s Expandable Cage Acquisition to Accelerate the Spine Division

    On January 3, DePuy Synthes, a subsidiary of Johnson & Johnson (JNJ), entered into an asset purchase and development agreement with Interventional Spine.

    By Sarah Collins
  • uploads///careadvantage
    Company & Industry Overviews

    Inside the Latest Capability Advancement in Johnson & Johnson’s Orthopedics

    On January 9, JNJ’s Medical Device division announced its Orthopedic Episode of Care Approach, a data-driven program that will accelerate value-based care.

    By Sarah Collins
  • uploads///revenues
    Company & Industry Overviews

    Analyzing Zimmer Biomet Holdings’ Financial Guidance for 2016

    Zimmer Biomet revised its 2016 guidance after reporting its 3Q16 earnings. Its guidance for fiscal 2016 is estimated to be $7.63 billion–$7.65 billion.

    By Sarah Collins
  • uploads///be medical
    Company & Industry Overviews

    BD’s Medical Segment Performance and Growth Strategy

    The BD Medical business generated revenues of ~$8.7 billion in fiscal 2016, which ended September 30, 2016.

    By Sarah Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.